Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
180000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status report for stock acquisition rights with an exercise price adjustment clause
発行・処分する株式数
Shares issued during the month: 180,000 new shares; treasury shares transferred: 0
Intended allottee
EVO FUND (allottee of the previously issued stock acquisition rights)
Existing Shares and Increase
+1.80%Rate of increase
27,384,392 shares27,564,392Shares
Exercise ratio during the month: 1.8%. Exercise ratio subject to the exercise restriction: 0.8%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price during the subject month: ¥140–¥149. The exercise price is subject to adjustment. The adjustment floor was not disclosed.
Number of Stock Acquisition Rights
Total issued: 100,000 rights. Exercised during the subject month: 1,800 rights. Unexercised at the end of the preceding month: 59,000 rights; unexercised at month-end: 57,200 rights.
Basis for determining the amount to be paid
Exercise price: ¥148 on 11 May 2026 and ¥146 on 22 May. The exercise prices on the other exercise dates were ¥148, ¥149, ¥147, ¥140, etc. The valuation basis and discount rate were not disclosed.
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restriction under Article 434 of the Listing Regulations. The monthly number of shares issued across all series was 180,000, the number of listed shares as of the payment date for the issuance was 22,284,392, and the exercise ratio subject to the exercise restriction was 0.8%.
Most recent equity financing
Timing 10 November 2025 / Type Issuance of the Second Series of Stock Acquisition Rights Issued in 2025 (with exercise price adjustment terms) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status report for stock acquisition rights with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | Shares issued during the month: 180,000 new shares; treasury shares transferred: 0 |
| Intended allottee | EVO FUND (allottee of the previously issued stock acquisition rights) |
| Dilution Rate | Exercise ratio during the month: 1.8%. Exercise ratio subject to the exercise restriction: 0.8% |
| Total number of issued shares | 27,384,392 shares (as of the end of the month preceding the subject month) → 27,564,392 shares (calculated as of the end of the subject month) |
| Basis for determining the amount to be paid | Exercise price: ¥148 on 11 May 2026 and ¥146 on 22 May. The exercise prices on the other exercise dates were ¥148, ¥149, ¥147, ¥140, etc. The valuation basis and discount rate were not disclosed. |
| Exercise price | Exercise price during the subject month: ¥140–¥149. The exercise price is subject to adjustment. The adjustment floor was not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 100,000 rights. Exercised during the subject month: 1,800 rights. Unexercised at the end of the preceding month: 59,000 rights; unexercised at month-end: 57,200 rights. |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restriction under Article 434 of the Listing Regulations. The monthly number of shares issued across all series was 180,000, the number of listed shares as of the payment date for the issuance was 22,284,392, and the exercise ratio subject to the exercise restriction was 0.8%. |
| Most recent equity financing | Timing 10 November 2025 / Type Issuance of the Second Series of Stock Acquisition Rights Issued in 2025 (with exercise price adjustment terms) / Amount Not disclosed |
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status in May 2026 of the Second Series of Stock Acquisition Rights Issued in 2025.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.